Eraxis

Eraxis

anidulafungin

Manufacturer:

Pfizer

Distributor:

DKSH
Concise Prescribing Info
Contents
Anidulafungin
Indications/Uses
Invasive candidiasis including candidemia & esophageal candidiasis in adults.
Dosage/Direction for Use
Adult Invasive candidiasis including candidemia 200 mg single loading dose on day 1, then 100 mg daily thereafter. Continue therapy for at least 14 days after the last positive culture, or based on patient's clinical response. Esophageal candidiasis 100 mg single loading dose on day 1, then 50 mg daily thereafter. Minimum of 14 days treatment and at least 7 days following resolution of symptoms. Continue therapy based on patient's clinical response. Max infusion rate: 1.1 mg/min.
Contraindications
Hypersensitivity to anidulafungin or other drugs of echinocandin class (eg, caspofungin).
Special Precautions
Anaphylactic & infusion related reactions. Monitor hepatic function in patients who develop abnormal liver function tests. Pregnancy & lactation. Childn <18 yr.
Adverse Reactions
Infusion-related events eg, rash, urticaria, flushing, pruritus, dyspnea, bronchospasm & hypotension. Thrombocytopenia, coagulopathy, hyperkalaemia, hypokalaemia, hypomagnesaemia, convulsion, headache, flushing, diarrhea; increased γ-glutamyltransferase, blood alkaline phosphatase, AST, ALT, bilirubin & blood creatinine; decreased platelet count, prolonged ECG QT.
MIMS Class
ATC Classification
J02AX06 - anidulafungin ; Belongs to the class of other systemic antimycotics.
Presentation/Packing
Form
Eraxis infusion 100 mg
Packing/Price
1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in